Your prediction
Pros and Cons of Advanced Proteome Therapeutics in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Cons
?
W********* I********* f** t** n*** y****
?
B****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Advanced Proteome Therapeutics vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Advanced Proteome Therapeutics | - | - | - | - | - | - | - |
| Larimar Therapeutics Inc. | -2.660% | -2.825% | -7.527% | 9.554% | 3.614% | -1.714% | -62.811% |
| Northwest Biotherapeutics Inc. | 0.000% | 36.364% | 12.500% | -7.216% | -12.621% | -59.641% | -83.636% |
| Achieve Life Sciences Inc. | 1.750% | 4.587% | 11.765% | 171.429% | 54.054% | 18.750% | -5.785% |
News
The $1.3 Trillion Inference War Is Heating Up. 3 Stocks to Watch.
Inference has become the fastest-growing part of the artificial intelligence (AI) infrastructure market, and Bloomberg Intelligence projects it will double the size of the AI training market by
Spectral AI Q2 Earnings Call Highlights
Key Points
- Interested in Spectral AI, Inc.? Here are five stocks we like better.
- FDA clearance is shifting Spectral AI toward commercialization: The company plans a disciplined U.S. and
NORMA Group Q2 Earnings Call Highlights
Key Points
- Interested in NORMA Group SE? Here are five stocks we like better.
- Profitability improved despite weak automotive demand: Q2 adjusted EBIT rose to EUR 7.6 million from EUR 2.3